ArticleHuman reproduction (Oxford, England)2012
Cell-free fetal DNA testing for fetal aneuploidy and beyond: clinical integration challenges in the US context.
Article in Human reproduction (Oxford, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Comparing the Introduction and Implementation of Noninvasive Prenatal Testing (NIPT) in Japan, the Netherlands, and the United States: An Integrative Review.Prenatal diagnosis · 2025Review
- Sequencing Newborns: A Call for Nuanced Use of Genomic Technologies.The Hastings Center report · 2018Article
- Expanding Use of cfDNA Screening in Pregnancy: Current and Emerging Ethical, Legal, and Social Issues.Current genetic medicine reports · 2017Article
- Developmental potential of clinically discarded human embryos and associated chromosomal analysis.Scientific reports · 2016Article
- Impact of Cell-Free Fetal DNA Screening on Patients' Choice of Invasive Procedures after a Positive California Prenatal Screen Result.Journal of clinical medicine · 2014Article
- Attitudes towards non-invasive prenatal testing for aneuploidy among US adults of reproductive age.Journal of perinatology : official journal of the California Perinatal Association · 2014Article
- Perinatal outcomes in euploid pregnancies with 'double-positive' first trimester prenatal screening for trisomy 18 and 21.Journal of perinatology : official journal of the California Perinatal Association · 2013Article
- Translating cell-free fetal DNA technology: structural lessons from non-invasive RhD blood typing.Trends in biotechnology · 2013Article
- Prenatal screening for fragile x: carriers, controversies, and counseling.Reviews in obstetrics & gynecology · 2013Article
- Informed decision-making about prenatal cfDNA screening: An assessment of written materials.Ethics, medicine, and public healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The recent release of new, non-invasive prenatal tests for fetal aneuploidy using cell-free fetal DNA (cffDNA) has been hailed as a revolution in prenatal testing and has triggered significant commercial interest in the field. Ongoing research portends the arrival of a wide range of cffDNA tests. However, it is not yet clear how these tests will be integrated into well-established prenatal testing strategies in the USA, as the timing of such testing and the degree to which new non-invasive tests will supplement or replace existing screening and diagnostic tools remain uncertain. We argue that there is an urgent need for policy-makers, regulators and professional societies to provide guidance on the most efficient and ethical manner for such tests to be introduced into clinical practice in the USA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.